Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company
What size range is anticipated for the Predictive Biomarkers Market from 2026 to 2030?
The predictive biomarkers market has demonstrated consistent expansion in recent years. Its valuation is set to climb from $20.96 billion in 2025 to $21.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.4%. This market’s past growth can be attributed to several factors including growth in genomic research, the rise in targeted therapies, increasing cancer prevalence, the expansion of molecular diagnostics, and regulatory support for biomarkers.
The predictive biomarkers market is anticipated to experience consistent expansion over the upcoming years, with its valuation projected to reach $25.65 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.0%. This projected growth during the forecast timeframe is attributable to several factors, including breakthroughs in multi-omics technologies, the broadening scope of personalized medicine, rising pharmaceutical research and development expenditure, a growing need for anticipatory treatment results, and the incorporation of biomarkers into standard medical practices. Key trends anticipated during this period encompass the wider application of precision oncology, an expanding role in stratifying drug responses, the increased design of clinical trials leveraging biomarkers, the growing uptake of companion diagnostics, and the establishment of standardized protocols for biomarker validation.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20595&type=smp
What Drivers Are Affecting Demand In The Predictive Biomarkers Market?
An anticipated increase in cancer incidents is set to fuel the expansion of the predictive biomarkers market. Cancer, a condition marked by uncontrolled cellular proliferation, can metastasize and affect various bodily regions. This surge in cancer cases primarily stems from demographic shifts towards older populations, evolving lifestyles, and heightened exposure to risk elements like tobacco use, poor dietary habits, and environmental contaminants. Within oncology, predictive biomarkers facilitate the identification of patients who are probable responders to particular treatments, thereby enabling tailored and more efficacious therapeutic interventions. For example, a report from April 2024 by the International Agency for Research on Cancer (IARC), a specialized cancer research agency based in France under the World Health Organization (WHO), indicated that 2022 saw almost 20 million new cancer cases and roughly 10 million cancer-related fatalities. Furthermore, forecasts predict the yearly count of new cancer cases will ascend to 35 million by 2050, which represents a 77% increment compared to 2022 figures. Consequently, the increasing incidence of cancer will be a key impetus for the expansion of the predictive biomarkers market.
Which Segments Are Gaining Traction In The Predictive Biomarkers Market?
The predictive biomarkers market covered in this report is segmented –
1) By Indication: Cancer, Metabolic Disease, Cardiovascular Disorder, Immunological Disorder, Other Indications
2) By Application: Screening, Analysis, Diagnosis, Prediction, Monitoring
3) By End User: Diagnostic Centers, Contract Research Organizations, Academic Research Institutes, Pharms And Biotech Companies, Other End Users
Subsegments:
1) By Cancer: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Leukemia And Lymphoma, Melanoma, Pancreatic Cancer, Kidney Cancer, Head And Neck Cancer
2) By Metabolic Disease: Type 1 And Type 2 Diabetes, Obesity, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease (NAFLD), Dyslipidemia, Insulin Resistance
3) By Cardiovascular Disorder: Atherosclerosis, Coronary Artery Disease, Heart Failure, Myocardial Infarction (Heart Attack), Arrhythmia, Hypertension, Stroke, Peripheral Arterial Disease
4) By Immunological Disorder: Autoimmune Diseases, Inflammatory Bowel Disease (Ibd), Multiple Sclerosis, Psoriasis, Allergic Diseases, Asthma, Chronic Obstructive Pulmonary Disease (Copd), Immunodeficiency Disorders
5) By Other Indications: Neurological Disorders, Infectious Diseases, Renal Diseases, Osteoarthritis, Genetic Disorders, Respiratory Disorders
Which Competitive Trends Are Impacting The Structure Of The Predictive Biomarkers Market?
Leading companies within the predictive biomarkers market are prioritizing the acceleration of biomarker development through technological innovations, such as artificial intelligence (AI)-driven biomarker discovery, to secure a competitive advantage by delivering more tailored and effective treatments expeditiously. AI-driven biomarker discovery facilitates the analysis of vast, intricate datasets, enabling the identification of predictive biomarkers that might not be discernible through conventional methods. For example, in July 2024, Scipher Medicine, Inc., a US-based precision immunology company, introduced PRoBeNet (Predictive Response Biomarkers using Network Medicine). This initiative aims to expedite the creation of predictive response biomarkers for complex illnesses by leveraging AI and network biology. PRoBeNet identifies biomarkers indicating therapy response by consolidating therapy-specific proteins and disease-characteristic molecular signatures. It has undergone validation for autoimmune conditions including rheumatoid arthritis, ulcerative colitis, and Crohn’s disease, and its application can be extended to other complex diseases and various phases of drug development.
Who Are The Top-Performing Companies In The Predictive Biomarkers Market In Recent Years?
Major companies operating in the predictive biomarkers market are Johnson & Johnson Services Inc, F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthcare GmbH, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Bio-Rad Laboratories Inc, QIAGEN GmbH, Almac Group Limited, ArcherDX Inc, Luminex Corporation, Guardant Health Inc, Meso Scale Diagnostics LLC, Myriad Genetics Inc, NanoString Technologies Inc, Fujirebio Inc, Asuragen Inc, Biognosys AG, Epigenomics AG, OncoCyte Corporation, Biomarker Technologies Inc
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/predictive-biomarkers-global-market-report
How Does The Predictive Biomarkers Market Perform Across Major Global Regions?
North America was the largest region in the predictive biomarkers market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Predictive Biomarkers Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20595&type=smp
Browse Through More Reports Similar to the Global Predictive Biomarkers Market 2026, By The Business Research Company
Renal Biomarkers Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report
Cancer Biomarker Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
Non Alcoholic Steatohepatitis Biomarkers Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company